Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/11467
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSLAETS, Leen-
dc.contributor.authorHENDRIKS, Jerome-
dc.contributor.authorSTINISSEN, Piet-
dc.contributor.authorKilpatrick, Trevor J.-
dc.contributor.authorHELLINGS, Niels-
dc.date.accessioned2011-01-09T08:29:09Z-
dc.date.availableNO_RESTRICTION-
dc.date.available2011-01-09T08:29:09Z-
dc.date.issued2010-
dc.identifier.citationTRENDS IN MOLECULAR MEDICINE, 16 (11). p. 493-500-
dc.identifier.issn1471-4914-
dc.identifier.urihttp://hdl.handle.net/1942/11467-
dc.description.abstractTherapies for multiple sclerosis (MS) reduce the relapse rate but are unable to stop neurological decline. Here, we evaluate the potential of leukemia inhibitory factor (LIF) as a novel therapeutic in diseases with a neurodegenerative and inflammatory component, such as MS. LIF, which can be a proinflammatory cytokine, can also modulate the immune response in a beneficial way. Recent evidence demonstrates a crucial role of LIF in neuroprotection and axonal regeneration as well as the prevention of demyelination. Finally, LIF is an important survival factor for stem cells and neuronal precursors. Therefore, we propose that LIF is a potential therapeutic candidate for MS.-
dc.language.isoen-
dc.publisherELSEVIER SCI LTD-
dc.subject.otherbiochemistry & molecular biology; cell biology; medicine, research & experimental-
dc.titleTherapeutic potential of LIF in multiple sclerosis-
dc.typeJournal Contribution-
dc.identifier.epage500-
dc.identifier.issue11-
dc.identifier.spage493-
dc.identifier.volume16-
local.format.pages8-
local.bibliographicCitation.jcatA1-
dc.description.notes[Slaets, Helena; Hendriks, Jerome J. A.; Stinissen, Piet; Hellings, Niels] Hasselt Univ, Biomed Res Inst, Diepenbeek, Belgium. [Slaets, Helena; Hendriks, Jerome J. A.; Stinissen, Piet; Hellings, Niels] Transnat Univ Limburg, Sch Life Sci, Diepenbeek, Belgium. [Kilpatrick, Trevor J.] Univ Melbourne, Ctr Neurosci, Melbourne, Vic 3010, Australia. [Kilpatrick, Trevor J.] Univ Melbourne, Howard Florey Inst, Melbourne, Vic 3010, Australia. 000284729500001-
local.type.refereedRefereed-
local.type.specifiedReview-
dc.bibliographicCitation.oldjcatA1-
dc.identifier.doi10.1016/j.molmed.2010.08.007-
dc.identifier.isi000284729500001-
item.fulltextWith Fulltext-
item.contributorSLAETS, Leen-
item.contributorHENDRIKS, Jerome-
item.contributorSTINISSEN, Piet-
item.contributorKilpatrick, Trevor J.-
item.contributorHELLINGS, Niels-
item.fullcitationSLAETS, Leen; HENDRIKS, Jerome; STINISSEN, Piet; Kilpatrick, Trevor J. & HELLINGS, Niels (2010) Therapeutic potential of LIF in multiple sclerosis. In: TRENDS IN MOLECULAR MEDICINE, 16 (11). p. 493-500.-
item.accessRightsRestricted Access-
item.validationecoom 2011-
crisitem.journal.issn1471-4914-
crisitem.journal.eissn1471-499X-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
slaets.pdf
  Restricted Access		Published version204.42 kBAdobe PDFView/Open    Request a copy
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.